The role of genetics in acute coronary syndrome

J. Chandrasekhar, R. Mehran

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is standard of care in acute coronary syndrome and is recommended for a period of 12months regardless of invasive revascularization. The antiplatelet action of these agents is governed by levels of active plasma metabolites, which may be influenced by genetic variations. Recently genotyping has gained considerable attention to identify patients who may demonstrate poor platelet responsiveness, as a potential method to improve long-term outcomes. However whether or not systematic genotyping will prove to be advantageous and cost-effective is the subject of on-going studies. This chapter discusses the current data on the impact of genetic variations with antiplatelet therapy, as well as the potential role of genotyping in prescription of antiplatelet therapies in acute coronary syndrome.

Original languageEnglish
Title of host publicationCardiovascular Diseases
Subtitle of host publicationGenetic Susceptibility, Environmental Factors and their Interaction
PublisherElsevier Inc.
Number of pages31
ISBN (Electronic)9780128033135
ISBN (Print)9780128033128
StatePublished - 19 Aug 2016


  • ABCB1
  • CYP1A2
  • CYP2C19
  • CYP3A4
  • Cost-effectiveness
  • Gain-of-function alleles
  • Genotyping
  • Loss-of-function alleles
  • Paraoxonase-1


Dive into the research topics of 'The role of genetics in acute coronary syndrome'. Together they form a unique fingerprint.

Cite this